Logo image of CYCC

CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Fundamental Analysis

NASDAQ:CYCC - Nasdaq - US23254L8019 - Common Stock

0.3532  -0.01 (-1.89%)

After market: 0.3501 0 (-0.88%)

Fundamental Rating

2

Overall CYCC gets a fundamental rating of 2 out of 10. We evaluated CYCC against 572 industry peers in the Biotechnology industry. CYCC may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CYCC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYCC has reported negative net income.
In the past year CYCC has reported a negative cash flow from operations.
In the past 5 years CYCC always reported negative net income.
In the past 5 years CYCC always reported negative operating cash flow.
CYCC Yearly Net Income VS EBIT VS OCF VS FCFCYCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

CYCC has a Return On Assets of -250.53%. This is amonst the worse of the industry: CYCC underperforms 92.74% of its industry peers.
Industry RankSector Rank
ROA -250.53%
ROE N/A
ROIC N/A
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
CYCC Yearly ROA, ROE, ROICCYCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYCC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCC Yearly Profit, Operating, Gross MarginsCYCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYCC has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CYCC has been increased compared to 5 years ago.
There is no outstanding debt for CYCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYCC Yearly Shares OutstandingCYCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
CYCC Yearly Total Debt VS Total AssetsCYCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -123.17, we must say that CYCC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -123.17, CYCC is doing worse than 98.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -123.17
ROIC/WACCN/A
WACC11.07%
CYCC Yearly LT Debt VS Equity VS FCFCYCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M 30M

2.3 Liquidity

CYCC has a Current Ratio of 0.77. This is a bad value and indicates that CYCC is not financially healthy enough and could expect problems in meeting its short term obligations.
CYCC's Current ratio of 0.77 is on the low side compared to the rest of the industry. CYCC is outperformed by 90.97% of its industry peers.
CYCC has a Quick Ratio of 0.77. This is a bad value and indicates that CYCC is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.77, CYCC is not doing good in the industry: 90.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
CYCC Yearly Current Assets VS Current LiabilitesCYCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.67% over the past year.
Looking at the last year, CYCC shows a very negative growth in Revenue. The Revenue has decreased by -80.83% in the last year.
CYCC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.87% yearly.
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%

3.2 Future

CYCC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.14% yearly.
CYCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 213.65% yearly.
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYCC Yearly Revenue VS EstimatesCYCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCC Yearly EPS VS EstimatesCYCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYCC. In the last year negative earnings were reported.
Also next year CYCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCC Price Earnings VS Forward Price EarningsCYCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCC Per share dataCYCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as CYCC's earnings are expected to grow with 25.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.85%
EPS Next 3Y25.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYCC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLACEL PHARMACEUTICALS INC

NASDAQ:CYCC (1/22/2025, 5:35:35 PM)

After market: 0.3501 0 (-0.88%)

0.3532

-0.01 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners18.63%
Inst Owner Change0%
Ins Owners2.48%
Ins Owner Change0%
Market Cap2.22M
Analysts43.33
Price Target1.02 (188.79%)
Short Float %2.17%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-38.18%
DP-0.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.51%
Min EPS beat(2)50.81%
Max EPS beat(2)68.2%
EPS beat(4)3
Avg EPS beat(4)42.12%
Min EPS beat(4)-3.64%
Max EPS beat(4)68.2%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)9
Avg EPS beat(12)22.73%
EPS beat(16)10
Avg EPS beat(16)7.81%
Revenue beat(2)1
Avg Revenue beat(2)4.58%
Min Revenue beat(2)-86.93%
Max Revenue beat(2)96.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-90.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)88.8%
EPS NY rev (1m)0%
EPS NY rev (3m)37.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.4
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0.01
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -250.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z -123.17
F-Score2
WACC11.07%
ROIC/WACCN/A
Cap/Depr(3y)42.56%
Cap/Depr(5y)135.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%
EBIT growth 1Y46.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.83%
OCF growth 3YN/A
OCF growth 5YN/A